Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Saturday, Teva Reports Patients With Tardive Dyskinesia Found AUSTEDO XR Easy To Take With Over 96% Agreement

Author: Benzinga Newsdesk | September 22, 2025 02:50am
  • Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR® (deutetrabenazine) extended-release tablets
  • Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatment
  • Almost all (>96%) patients relayed that AUSTEDO XR was easy to take

Posted In: TEVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist